Millennium Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-113,300
| Closed | -$419K | – | 4352 |
|
|
2017
Q4 | $419K | Buy |
113,300
+51,000
| +82% | +$209K | ﹤0.01% | 3181 |
|
|
2017
Q3 | $255K | Buy |
+62,300
| New | +$238K | ﹤0.01% | 3127 |
|
|
2017
Q2 | – | Sell |
-342,351
| Closed | -$1.42M | – | 4115 |
|
|
2017
Q1 | $1.42M | Buy |
342,351
+295,215
| +626% | +$1.24M | ﹤0.01% | 2200 |
|
|
2016
Q4 | $203K | Sell |
47,136
-26,293
| -36% | -$170K | ﹤0.01% | 3076 |
|
|
2016
Q3 | $723K | Sell |
73,429
-32,808
| -31% | -$233K | ﹤0.01% | 2437 |
|
|
2016
Q2 | $601K | Buy |
+106,237
| New | +$721K | ﹤0.01% | 2401 |
|
|
2016
Q1 | – | Sell |
-21,951
| Closed | -$292K | – | 3887 |
|
|
2015
Q4 | $292K | Sell |
21,951
-4,466
| -17% | -$76.9K | ﹤0.01% | 2916 |
|
|
2015
Q3 | $434K | Sell |
26,417
-35,180
| -57% | -$721K | ﹤0.01% | 2727 |
|
|
2015
Q2 | $1.38M | Sell |
61,597
-90,483
| -59% | -$1.43M | ﹤0.01% | 2111 |
|
|
2015
Q1 | $1.49M | Buy |
152,080
+22,913
| +18% | +$225K | ﹤0.01% | 2122 |
|
|
2014
Q4 | $1.47M | Buy |
129,167
+12,500
| +11% | +$136K | ﹤0.01% | 2213 |
|
|
2014
Q3 | $1.34M | Buy |
116,667
+77,223
| +196% | +$1.18M | ﹤0.01% | 2113 |
|
|
2014
Q2 | $767K | Sell |
39,444
-9,961
| -20% | -$176K | ﹤0.01% | 2345 |
|
|
2014
Q1 | $886K | Sell |
49,405
-17,262
| -26% | -$283K | ﹤0.01% | 2292 |
|
|
2013
Q4 | $704K | Hold |
66,667
| – | – | ﹤0.01% | 2506 |
|
|
2013
Q3 | $824K | Sell |
66,667
-285,032
| -81% | -$3M | ﹤0.01% | 2241 |
|
|
2013
Q2 | $3.31M | Buy |
+351,699
| New | +$4.52M | 0.01% | 1277 |
|
Millennium Management's CASC Position: Q1 2018 in Review
Millennium Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 113,300 shares — an estimated $419K sold.
Millennium Management first reported a position in CASC in Q2 2013 and held it in 17 quarters. The position peaked at $3.31M in Q2 2013. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Millennium Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Millennium Management sold 113,300 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $419K.
- Millennium Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 17 quarters.
- Millennium Management's Cascadian Therapeutics, Inc. position peaked at $3.31M in Q2 2013.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Millennium Management's 13F filing for Q1 2018, filed 15 May 2018.